Versartis, Inc. (NASDAQ:VSAR) Director Srinivas Akkaraju purchased 419,700 shares of the stock in a transaction dated Friday, December 1st. The shares were bought at an average price of $2.13 per share, for a total transaction of $893,961.00. Following the completion of the acquisition, the director now owns 14,955 shares in the company, valued at $31,854.15. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Srinivas Akkaraju also recently made the following trade(s):

  • On Monday, December 4th, Srinivas Akkaraju acquired 513,872 shares of Versartis stock. The stock was acquired at an average price of $2.21 per share, with a total value of $1,135,657.12.

Versartis, Inc. (NASDAQ VSAR) remained flat at $$2.03 during trading hours on Tuesday. The stock had a trading volume of 906,910 shares, compared to its average volume of 814,075. Versartis, Inc. has a 1-year low of $1.60 and a 1-year high of $24.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the business earned ($0.92) EPS. analysts expect that Versartis, Inc. will post -4.14 EPS for the current fiscal year.

A number of brokerages recently issued reports on VSAR. Piper Jaffray Companies cut shares of Versartis from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $26.00 to $4.00 in a report on Friday, September 22nd. ValuEngine cut shares of Versartis from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Barclays cut shares of Versartis from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $28.00 to $4.00 in a report on Friday, September 22nd. Citigroup lowered shares of Versartis from a “buy” rating to a “neutral” rating and cut their target price for the stock from $23.00 to $3.00 in a research report on Monday, September 25th. Finally, SunTrust Banks lowered shares of Versartis from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $4.00 in a research report on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $7.22.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Versartis by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after purchasing an additional 118,894 shares in the last quarter. State Street Corp grew its stake in Versartis by 6.9% during the second quarter. State Street Corp now owns 556,718 shares of the biopharmaceutical company’s stock worth $9,716,000 after buying an additional 35,957 shares during the last quarter. Northern Trust Corp grew its stake in Versartis by 15.6% during the second quarter. Northern Trust Corp now owns 420,553 shares of the biopharmaceutical company’s stock worth $7,339,000 after buying an additional 56,761 shares during the last quarter. Artal Group S.A. grew its stake in Versartis by 14.3% during the third quarter. Artal Group S.A. now owns 400,000 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 50,000 shares during the last quarter. Finally, Sphera Funds Management LTD. grew its stake in Versartis by 25.8% during the second quarter. Sphera Funds Management LTD. now owns 377,524 shares of the biopharmaceutical company’s stock worth $6,588,000 after buying an additional 77,524 shares during the last quarter. 49.18% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/srinivas-akkaraju-buys-419700-shares-of-versartis-inc-vsar-stock.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.